Researching insulin resistance
Researchers are studying the effects of insulin on the brain and brain cell function, and insulin changes in the brain that may be related to Alzheimer's. A trial is testing an insulin nasal spray to determine if it slows the progression of Alzheimer's.
Studying the heart-head connection
Growing evidence suggests that brain health is closely linked to heart and blood vessel health. Your arteries nourish your brain. The risk of developing Alzheimer's appears to increase as a result of many conditions that damage the heart or arteries. These include high blood pressure, heart disease, stroke, diabetes and high cholesterol.
In addition, a strong genetic Alzheimer's risk factor is one form of a gene for a protein that carries cholesterol in the blood (apolipoprotein E).
A number of studies are exploring how best to build on this heart-head connection. Strategies under investigation include:
- Current drugs for heart disease risk factors. Researchers are investigating whether drugs now used to treat high blood pressure, diabetes and high cholesterol may also help people with Alzheimer's or reduce the risk of developing the disease.
- Drugs aimed at new targets. Additional projects are looking more closely at how the connection between heart disease and Alzheimer's works at the molecular level to find new drug targets.
- Lifestyle choices. Researchers have explored whether lifestyle choices with known heart benefits, such as exercising on most days and eating a heart-healthy diet, may help prevent Alzheimer's disease or delay its onset.
Researching thinking and social activities
Studies research whether thinking (cognitive) activities, such as memory training, may help prevent or delay Alzheimer's.
Researchers also are studying whether social interaction may positively affect cognitive function.
Speeding treatment development
Developing new medications is a slow and painstaking process. The pace can be especially frustrating for people with Alzheimer's and their families who are waiting for new treatment options.
To help accelerate discovery, the Coalition Against Major Diseases (CAMD), an alliance of pharmaceutical companies, nonprofit foundations and government advisers, have forged a first-of-its-kind partnership to share data from Alzheimer's clinical trials.
Researchers anticipate that sharing these data from more than 4,000 study participants will speed development of more-effective therapies.
March 06, 2013
- Current Alzheimer's treatments. Alzheimer's Association. http://www.alz.org/research/science/alzheimers_disease_treatments.asp#. Accessed Jan. 4, 2013.
- Treatment horizon. Alzheimer's Association. http://www.alz.org/research/science/alzheimers_treatment_horizon.asp. Accessed Jan. 3, 2013.
- Uzun S, et al. Alzheimer's dementia: Current data review. Collegium Antropologicum. 2011;35:1333.
- Galimberti D, et al. Progress in Alzheimer's disease. Journal of Neurology. 2012;259:201.
- Press D, et al. Prevention of dementia. http://www.uptodate.com/home. Accessed Dec. 20, 2012.
- Coalition against major diseases (CAMD). U.S. Food and Drug Administration. http://www.fda.gov/AboutFDA/PartnershipsCollaborations/PublicPrivatePartnershipProgram/ucm231134.htm. Accessed Jan. 4, 2013.
- Romero K, et al. The Coalition Against Major Diseases: Developing tools for an integrated drug development process for Parkinson's and Alzheimer's diseases. Clinical Pharmacology & Therapeutics. 2009;86:365.
- Prevention and risk of Alzheimer's and dementia. Alzheimer's Association. http://www.alz.org/research/science/alzheimers_prevention_and_risk.asp. Accessed Jan. 16, 2013.
- Preventing Alzheimer's disease: What do we know? National Institute on Aging. http://www.nia.nih.gov/alzheimers/publication/preventing-alzheimers-disease/search-alzheimers-prevention-strategies. Accessed Jan. 16, 2013.